| 2D | Two-dimensional |
| 3D | Three-dimensional |
| AJCC | American Joint Commission on Cancer |
| AKT | Protein kinase B |
| BCL-2 | B-cell lymphoma-2 |
| BCL-XL | B-cell lymphoma-extra large protein |
| BRAF | v-Raf murine sarcoma viral oncogene homolog B |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CTCs | Circulating tumor cells |
| ctDNA | Circulating tumor DNA |
| CTLA-4 | T-lymphocyte-associated protein |
| CT | Computed tomography |
| DDR | DNA damage repair |
| EMT | Epithelial mesenchymal transition |
| EpCAM | Epithelial cell adhesion molecule |
| ERK | Extracellular Signal-Regulated Kinase |
| FDA | Food and Drug Administration |
| HIF-1α | Hypoxia-inducible factor-1α |
| HiRIEF LC-MS/MS | High-resolution isoelectric focusing liquid chromatography-mass spectrometry |
| HR | Homologous recombination |
| ICI | Immune checkpoint inhibitor |
| IFN | Interferon |
| IL | Interleukin |
| IMPRES | IMmuno-PREdictive Score |
| ITS | Immunotherapy score |
| KIT | v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog |
| LDH | lactate dehydrogenase |
| MAP3K | Mitogen-activated protein kinase kinase |
| MAPK | Mitogen-activated protein kinase |
| MCL-1 | Myeloid leukemia cell differentiation |
| MEK | Mitogen-activated protein kinase kinase |
| MHC | Major histocompatibility complex |
| miR | microRNA |
| MRI | Magnetic Resonance Imaging |
| NF1 | Neurofibromin 1 |
| NFκB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NGS | Next-generation-sequencing |
| NL | Neoantigen load |
| NRAS | Neuroblastoma RAS viral oncogene homolog |
| OS | Overall Survival |
| PD1 | Programmed cell death protein 1 |
| PDL1 | Programmed death-ligand 1 |
| PEAs | Proximity extension assays |
| PFS | Progression Free Survival |
| PI3K | Phosphoinositol-3-kinase |
| PIP2 | Phosphatidylinositol (4,5)-bisphosphate |
| PIP3 | Phosphatidylinositol (3,4,5)-trisphosphate |
| PET | Positron Emission Tomography |
| PTEN | Phosphatase and tensin homolog deleted on chromosome 10 |
| RECIST | Response Evaluation Criteria in Solid Tumours |
| RFS | Shorter relapse-free survival |
| RNA-seq | Fast RNA sequencing |
| STAT3 | Signal transducer and activation of transcription-3 |
| TA | Texture analysis |
| TERC | Telomerase RNA component |
| TERT | Telomerase reverse transcriptase |
| TGF-β | Transforming Growth Factor-β |
| TILs | Tumor-infiltrating lymphocytes |
| TMB | Tumor mutational burden |
| VEGF | Vascular endothelial growth factor |